| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8223286 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 7 Pages |
Abstract
Patients with favorable intermediate-risk prostate cancer did not benefit from the addition of ADT to dose-escalated RT, and their FFF was nearly as good as patients with low-risk disease. In patients with GS 4+3 or T2c disease, the addition of ADT to dose-escalated RT did improve FFF.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Katherine O. MD, Karen E. MD, MHSc, MPH, Lawrence B. MS, Andrew K. MD, MPH, Seungtaek MD, Quynh N. MD, Steven J. MD, Thomas J. MD, Sean E. MD, PhD, Deborah A. MD,